NO20092527L - Prolegemidler, fremgangsmate for fremstilling og anvendelse derav - Google Patents

Prolegemidler, fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO20092527L
NO20092527L NO20092527A NO20092527A NO20092527L NO 20092527 L NO20092527 L NO 20092527L NO 20092527 A NO20092527 A NO 20092527A NO 20092527 A NO20092527 A NO 20092527A NO 20092527 L NO20092527 L NO 20092527L
Authority
NO
Norway
Prior art keywords
drug
parent
parent drug
manufacture
drugs
Prior art date
Application number
NO20092527A
Other languages
English (en)
Norwegian (no)
Inventor
Naweed Muhammad
Keith R Bley
Original Assignee
Neurogesx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogesx Inc filed Critical Neurogesx Inc
Publication of NO20092527L publication Critical patent/NO20092527L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20092527A 2006-12-05 2009-07-03 Prolegemidler, fremgangsmate for fremstilling og anvendelse derav NO20092527L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87351906P 2006-12-05 2006-12-05
PCT/US2007/024984 WO2008070149A2 (fr) 2006-12-05 2007-12-05 Promédicaments et procédés pour les fabriquer et les utiliser

Publications (1)

Publication Number Publication Date
NO20092527L true NO20092527L (no) 2009-09-04

Family

ID=39361296

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092527A NO20092527L (no) 2006-12-05 2009-07-03 Prolegemidler, fremgangsmate for fremstilling og anvendelse derav

Country Status (12)

Country Link
US (1) US20080318905A1 (fr)
EP (1) EP2121029A2 (fr)
JP (1) JP2010511717A (fr)
KR (1) KR20090086627A (fr)
CN (1) CN101678120A (fr)
AU (1) AU2007328007A1 (fr)
BR (1) BRPI0719937A2 (fr)
CA (1) CA2671737A1 (fr)
MX (1) MX2009006007A (fr)
NO (1) NO20092527L (fr)
RU (1) RU2009125597A (fr)
WO (1) WO2008070149A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US20100094001A1 (en) * 2007-03-06 2010-04-15 Eisai R&D Management Co., Ltd. Composition containing stability-improved chloromethyl phosphate derivative and process for producing same
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8735376B2 (en) 2008-05-20 2014-05-27 Acorda Therapeutics, Inc. Carbonate prodrugs and methods of using the same
WO2009143299A1 (fr) 2008-05-20 2009-11-26 Neurogesx, Inc. Promédicaments mutuels d'acétaminophène et d'hépatoprotecteur
RU2010151952A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Водорастворимые аналоги ацетаминофена
UA99198C2 (ru) 2008-07-28 2012-07-25 Пфайзер Інк. Соединения фенантренона, композиция, содержащая их, и способ лечения
US20100076198A1 (en) * 2008-09-19 2010-03-25 Mallinckrodt Inc. Crystalline forms of Fentanyl Alkaloid
ES2639065T5 (es) 2009-06-25 2023-01-30 Alkermes Pharma Ireland Ltd Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
EP2445343B1 (fr) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Promédicaments de composés nh acides
CA2802733C (fr) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments de composes nh-acides : derives esters, carbonates, carbamates et phosphonates
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
PT2736510T (pt) * 2011-07-28 2017-04-05 Kempharm Inc Pró-fármacos de metilfenidato, processos de preparação e utilização dos mesmos
JP6029670B2 (ja) 2011-09-22 2016-11-24 アコーダ セラピューティクス、インク． アセトアミノフェンコンジュゲートおよびその組成物ならびにその使用方法
WO2013088255A1 (fr) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
WO2013142198A1 (fr) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
CA2867123C (fr) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Compositions pharmaceutiques renfermant des agents antipsychotiques non hydrosolubles et des esters glycerol
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
EP3718536A1 (fr) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Compositions pharmaceutiques présentant une stabilité améliorée au stockage
EP2986295A4 (fr) 2013-04-17 2016-11-09 Biopharma Works Composés destinés au traitement de la douleur
WO2014172478A1 (fr) 2013-04-17 2014-10-23 VOLKMANN Robert Composés destinés au traitement de la douleur
WO2014188266A1 (fr) 2013-05-24 2014-11-27 Rhodes Technologies Composés cétal opioïdes et leurs utilisations
EP3077398B1 (fr) 2013-12-05 2020-03-11 The University of Bath Nouveaux composés opioïdes et leurs utilisations
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
RU2728721C2 (ru) * 2015-05-13 2020-07-30 4П-Фарма Композиции стимуляторов, предотвращающие злоупотребление ими
US20170273974A1 (en) * 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
EP3703694A4 (fr) * 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. Promédicaments antagonistes des récepteurs opioïdes
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
WO2020012248A1 (fr) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Nouveaux composés de naphtylényle pour compositions injectables à action prolongée et procédés associés
EA202190966A1 (ru) * 2018-10-13 2021-10-15 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Пролекарства антагонистов cgrp
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
FI130262B (en) * 2019-08-30 2023-05-17 Medicortex Finland Oy Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases
AU2020360928A1 (en) * 2019-09-30 2022-04-14 Nippon Chemiphar Co., Ltd. Azepan derivative
CN114380859A (zh) * 2020-10-22 2022-04-22 威智医药有限公司 磷酸二苄酯及焦磷酸四苄酯的制备方法
CN117805249A (zh) * 2022-09-23 2024-04-02 合肥瀚微生物科技有限公司 一种抑郁症诊断的生物标记物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
PT1685839E (pt) * 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
EP1051181B1 (fr) * 1997-12-31 2004-03-17 The University Of Kansas Remedes contenant des precurseurs hydrosolubles d'amines tertiaires, et leurs procedes d'obtention
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
CA2518834A1 (fr) * 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Composes et methodes pour reduire l'abus potentiel d'un medicament et pour en prolonger la duree d'action
ES2653568T3 (es) * 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso

Also Published As

Publication number Publication date
CN101678120A (zh) 2010-03-24
CA2671737A1 (fr) 2008-06-12
AU2007328007A1 (en) 2008-06-12
WO2008070149A2 (fr) 2008-06-12
US20080318905A1 (en) 2008-12-25
KR20090086627A (ko) 2009-08-13
WO2008070149A3 (fr) 2009-12-10
BRPI0719937A2 (pt) 2014-03-11
MX2009006007A (es) 2009-07-17
JP2010511717A (ja) 2010-04-15
RU2009125597A (ru) 2011-01-20
EP2121029A2 (fr) 2009-11-25

Similar Documents

Publication Publication Date Title
NO20092527L (no) Prolegemidler, fremgangsmate for fremstilling og anvendelse derav
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
NZ726256A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2008157103A3 (fr) Formes de dosage solides ou semi-solides à libération modifiée
WO2008058547A3 (fr) Composition d'alpha-lactalbumine
WO2007070052A3 (fr) Compositions pharmaceutiques et méthodes destinées à traiter ou prévenir une maladie associée à l'oxalate
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
WO2010033236A3 (fr) Procédés et compositions pour le traitement d'infections bactériennes par l'inhibition de la détection du quorum
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
WO2007064448A3 (fr) Traitement du cancer a l'aide de fts et de 2-desoxyglucose
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
WO2009001209A8 (fr) Utilisation de conjugués d'acide d'hyaluronique dans le traitement local de maladies de peau hyperprolifératives
MA32635B1 (fr) Produit medicamenteux et traitement associe
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
WO2007149816A3 (fr) Compositions de strontium et méthodes de traitement d'affections ostéoporotiques

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application